Investors can get attractive profits from any of these powerful stocks using just $1,000.

1. TSM

An exceptionally good way to spend your $1,000 wisely is to buy shares of Taiwan Semiconductor Manufacturing.

The spike in demand for electronics has added to the already heightened chip demand from areas like 5G and the Internet of Things, high-performance computing, and AI. However, supply chain problems and geopolitical tensions have resulted in a global chip shortage. TSM is now trying to to assuage this problem and announced plans to invest $100 billion over three years in capacity and R&D.

The company does however expect a demand-supply mismatch until 2022. Yet TSM is currently 57% of global chip production, the company is positioned to benefit from this with higher pricing.

While competitors like Intel (INTC) and Samsung have unveiled expansion plans, their success is far from certain. Against this backdrop, TSM seems a superior pick, especially since it pays a dividend yield of near 1.5%. Hence, although TSM is at 11.6 times trailing-12-month sales, which isn’t cheap, but investors can still bring in robust returns from this stock.

2. Nio

Investors might also invest their $1,000 into Nio for some great profits. This stock has gone down over 38% from its high of $66.99 in early January of this year. The company’s problems come mainly from retail investors changing away from growth stocks and into value stocks. The company also missed its consensus earnings estimate in Q4 of last year.

Despite all these problems, the underlying strength of Nio are very strong. In 2020, China was 41% of global EV sales. Estimates say that 1.9 million EVs will be sold in the country this year, a y/y increase of 51%.

While EVs will account for 9% of total auto sales in China, the percentage is expected to expand to 35% by 2025. Nio is well stationed to gain a significant share of this increasing market.

Nio is also now guiding for Q1 revenues in between $1.13 billion to $1.16 billion, which means a y/y growth of between 438% to 451%. These estimates match Nio’s 423% y/y increase in vehicle sales to 20,060 units.

With Nio trading at 25.7 times trailing-12-month sales, which is high. Investors can still get handsome profits from this stock even at elevated levels, considering that Nio has a bold strategy to capture the huge opportunity in China.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

3. Gilead Sciences

Finally, Gilead Sciences is also a smart place to invest $1,000, especially for risk-averse investors. The company gives a solid dividend of 4.3%, much greater than the S&P’s yield of 1.4%. With a trailing-12-month sales dividend ratio of 46.25%, the company is flexible enough to keep its dividend policy going into the long-term future.

However, this stock has lowered by over 15.8% in the past year. The first covid treatment for patients approved by the FDA, Veklury, may soon decline as more vaccinations lower the number of people getting treatment. In November of last year, the WHO even recommended against Veklury, which hurt the drug’s sales.

But there is more to Gilead Sciences than the Covid drug Veklury. The company also has a very strong foothold in the HIV market and is developing a presence inside the oncology sector. To offset older HIV drugs like Truvada and Atripla being phased out, the company has been focusing on creating new HIV drugs with better safety. The company’s recently released HIV drug, Biktarvy, is the top drug for HIV patients in the States. The company also expects to apply to the FDA for Lenacapavir as a six month treatment for HIV patients. In oncology, Gilead Sciences is using cell therapy drug Trodelvy and Yescarta, a drug for breast cancer. Additionally, Trodelvy has the possibility to be approved for several other tumor indications.

Gilead Sciences brought in $5 billion or almost 67% of its total cash to shareholders using their dividends and share repurchases last year. Despite many attractive possibilities and achievements, the stock is trading at just 3.3 times trailing-12-month sales. Making it an attractive bet for income investors and value investors.

Three stocks in this excellent category of routine dividend growth are utility Consolidated Edison (ED), Canadian energy company Enbridge (ENB), and real estate investment trust Realty Income (O). Let’s discuss these world-class stocks right now.

Consolidated Edison

Consolidated Edison is reaching an important dividend marker. The utility that gives electricity to the NY City area has boosted its payout for 47 straight years. That puts it only three years away from joining a top group of dividend heavyweights.

Consolidated Edison seems to be on track to get that rare honor. The company expects to increase its earnings per share by between 4% and 6% yearly over the next five years. Underlying that forecast is the recovery and expansion of the New York City market and the company’s solar energy business, where it is the second-largest solar energy creator in North America and seventh largest globally. Consolidated has plenty financial ability to fund the capital projects needed to keep growing its earnings, thanks to its investment-grade numbers and relatively conservative dividend ratio. It should stay a world-class dividend asset for years.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

Enbridge

Enbridge has boosted its dividend in every year of the past 26. But even more impressive, it has an excellent dividend growth rate. The company has increased its payout at a 10% compound rate during the past 26 years. 

That’s a stellar track record, especially in the rough energy industry. The company’s heavy dividend growth has delivered the ability to generate great returns of 15% annually over the past 25 years, well ahead of the S&P 500 and its peers.

Enbridge should continue growing its dividend in the years to come. The company has a multi-billion-dollar expansion program happening now that should deliver 5% to 7% per share growth through 2023. 

Beyond that, it keeps moving its investments into infrastructure that supports low carbon sources. Enbridge also has good financial flexibility to pay for this growth thanks to its investment-level numbers and conservative payout ratio. 

Realty Income

Realty Income has been perfect over the years. The REIT has given out 610 consecutive monthly dividends since it began over half a century ago. And since 1994, the REIT has boosted its payout 110 times, including in each of the past 94 quarters.

Overall, Realty Income has enlarged its payout at a 4.4% compound rate since its IPO. That has helped it create a 15.2% yearly average return as a company.

Realty Income should not have a problem continuing this trend. It has one of the best balance sheets in the industry as it’s one of only eight REITs with A-rated credit. And with its conservative dividend ratio, it has the financial flexibility to keep buying new properties, which drives its growth and payout. 

Recently, two biotech firms have peaked the interest of Reddit traders. The allure of these two companies has much to do with their triple or even quadruple-digit gains over the past year.

There’s only one problem: When you look forward five-years, both of these stocks look deeply in the red.

Has Reddit selected another group of besieged businesses yet again, or are these two stocks in fact, turnaround stories that could make you rich?

1. Ocugen

Ocugen (OCGN) is a Reddit pick in part due to it co-developing and making a coronavirus vaccine that was originally created by Bharat Biotech. Given the world’s large demand for vaccines, the short-term potential of this deal could be huge. There is lots of room for more coronavirus vaccines to be given, but the details are where I believe Reddit has it wrong.

Bharat Biotech’s “Covaxin” vaccine has been proven to be effective and safe in phase 3 trials, but it has not received approval yet in America. That’s an issue.

Also, Ocugen’s deal to monetize only covers America, where vaccination is rapidly progressing with other vaccines already approved for sale. So, the revenue potential is maybe less than Reddit traders are wishing for.

Then, there is the fact that Ocugen will get just 45% of the profits from sales in America. The company is an early-stage biotech that does not yet have any clinical development projects and it is not a drug maker.

Without a history of profitably manufacturing anything and with a product developed completely by another company, it looks to be on shaky ground and investors should know it is much riskier than it might seem at first.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

2. Humanigen

Humanigen (HGEN) is another biotech company that Reddit loves and is also doing a coronavirus project. Instead of a vaccine, the company is developing its antibody therapy lenzilumab in phase 3 trials to test its effectiveness at saving COVID-19 patients.

In its recent update in March, the company reported that lenzilumab reduced the chances of needing a ventilator by up to 54%. That’s a very promising development, and investors should be excited. But again, the details are more complicated.

Certain populations are more likely to have a severe covid case when compared to younger people. But also, these vulnerable people are the ones most likely to be vaccinated against the disease. Around 65.9% of adults over 65 are already vaccinated. And those numbers will only go up.

So, with the market size decreasing, and Humanigen still having to finish its phase 3 trials and apply for approval before it can even start bringing in revenue. It’s obvious that Humanigen’s drug will save lives, but that does not mean a fortune for the company or the investors who invest in it.

Amazon (AMZN) has announced this week it will start using biometric technology at a Whole Foods store in Seattle that will let customers pay for their purchases with nothing but a scan of their palm print.

The system, called Amazon One, lets users link a credit card to their palm print, which they can use for payment.

Other Whole Foods locations will offer the technology soon, and this could be just the beginning. Amazon intends to license this technology, which it says will have a wide range of benefits for access and payments, including at stadiums, retail stores, and offices.

Amazon One was rolled out at the company’s cashierless Amazon Go stores to aid its entry. To sign up, customers simply put their card into a reader, hold their palm over the device, then follow the guide to link their card to their palm print.

This Tiny Square Could Solve The Supply Chain Crisis -- And Make You Rich

Democrats don't want conservative Patriots to know about this tiny square that could save American from Biden's failures....

Watch The Video

89,473

The technology uses computer vision to analyze the lines of the palm, creating a personal digital signature in seconds. Once sign-up is done, customers simply hold their palm over the contactless device at checkout to process a payment.

The e-commerce leader created the system to improve user experiences, including at checkout counters, entering a location, or showing a badge at work. Amazon says the tech is a “fast, reliable, and secure solution to identify people or authorize a transaction.”